Medincell (XPAR:MEDCL) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:MEDCL Medincell SA XPAR:MEDCL
77 GF Score
Price €26.88
GF Value €21.90
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Medincell FFO?

FFO (Funds from operations) only applies to REITs.

XPAR:MEDCL
77GF Score
Medincell SA XPAR:MEDCL
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Medincell (XPAR:MEDCL) Overvalued in 2026?

Based on GuruFocus' analysis, Medincell stock appears to be overvalued. The current stock price of €26.88 is trading 22.7% above its estimated GF Value™ of €21.90. GuruFocus considers Medincell to be Modestly Overvalued.

Key valuation signals for XPAR:MEDCL:

  • FFO:
  • GF Value™: €21.90 vs. price of €26.88 (22.7% above fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the XPAR:MEDCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medincell Business Description

Other Exchanges 0ACH:UKMEDCLp:UKMEB:Germany
Address 3 rue des Freres Lumiere, Jacou, FRA, 34830
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
77GF Score

Get the complete analysis for XPAR:MEDCL

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€26.88
Price
€21.90
GF Value